Ubs Asset Management Americas Inc Moon Lake Immunotherapeutics Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 19,164 shares of MLTX stock, worth $175,542. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,164
Previous 43,804
56.25%
Holding current value
$175,542
Previous $1.71 Million
47.17%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding MLTX
# of Institutions
157Shares Held
54.5MCall Options Held
799KPut Options Held
661K-
Bvf Inc San Francisco, CA19.8MShares$181 Million36.63% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$77.8 Million40.43% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.15MShares$38 Million3.57% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.61MShares$23.9 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.67MShares$15.3 Million0.01% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $338M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...